VC Funding Top Ten — October 15, 2026: Ramp's $1.85B, AI Dominance, Biotech IPO

Overview

Thursday afternoon, October fifteenth. Today's biggest check is a monster: fintech platform Ramp just locked in one-point-eight-five billion dollars at a sixty billion dollar valuation. That's the headline in a busy day for venture capital. We're tracking ten major rounds today. Let's break it down with our Markets and

In this show

• Thursday afternoon, October fifteenth. Today's biggest check is a monster: fintech platform Ramp just locked in one-point-eight-five billion dollars at a sixty billion dollar valuation. That's the headline in a busy day for venture capital. We're tracking ten major rounds today. Let's break it down with our Markets and World analysts.
• Across the ten deals we're tracking, total disclosed funding hit two-point-six-four billion dollars. The hottest category was AI, accounting for five of the top ten rounds. And beyond venture, AI-driven biotech firm Iambic Therapeutics priced a successful one-hundred-fifty-million-dollar IPO on the Nasdaq. But the story of the day remains Ramp's massive funding, signaling intense investor confidence in the corporate finance automation sector.
• Let's dive into that number one deal. Ramp, the finance automation platform, raised one-point-eight-five billion dollars in a late-stage round led by Dragoneer Investment Group. This sets a new sixty-billion-dollar valuation for the company, which provides corporate cards, expense management, and AP services. This massive capital injection underscores the explosive growth in the corporate fintech space and solidifies Ramp's leadership position.
• Coming in at number two, OMass Therapeutics secured three hundred ten million dollars in an oversubscribed Series C. The round was co-led by Bain Capital Life Sciences, Forbion, and Novo Holdings. OMass develops small molecule drugs for rare and immunological diseases. This funding is critical as it will advance their lead program for congenital adrenal hyperplasia through Phase Two clinical trials, a major milestone for patients with the condition.
• Our number three spot is a public market debut. Iambic Therapeutics priced its IPO, raising one hundred fifty million dollars on the Nasdaq. The offering gives the AI-driven biotech company an initial market valuation of eight hundred nine million dollars. Iambic uses its artificial intelligence platform to discover and develop new cancer therapies. This successful IPO provides the capital needed to push its pipeline of AI-discovered oncology drugs through clinical trials.
• At number four, we have a big bet on the future of AI infrastructure. Mueon raised sixty-five million dollars in a Series A led by Maverick Silicon. The company is developing a modular compute and memory platform specifically for AI and hyperscale data centers. This funding is aimed at scaling its semiconductor systems, which are designed to drastically improve power and cost efficiency for the massive compute clusters that power modern AI.
• Securing the number five slot is Harmonic Security, which closed a fifty-million-dollar Series B round. Crosspoint Capital Partners led the investment. Harmonic provides a security platform built for the age of workforce AI, enabling enterprises to safely adopt and manage artificial intelligence tools for their employees. As companies rush to deploy AI, this investment will fuel Harmonic's growth to meet the rising demand for specialized AI security solutions.
• At number six, AI continues its push into healthcare. Confido Health raised twelve-point-five million dollars in a Series A extension led by Z47. The company builds AI agents designed to automate burdensome healthcare administration tasks, such as patient follow-up calls and appointment scheduling. This new capital will help expand its platform, aiming to free up doctors and nurses from administrative work to focus on patient care.
• Moving to number seven, we see fintech innovation in Southeast Asia. Salary Hero, a financial health platform, raised seven-point-six million dollars in a Series A led by Cento Ventures. The company provides employees with earned wage access and other financial wellness tools. The funding is earmarked for expansion into Malaysia, as the company scales its mission to improve the financial stability of workers across the region.
• At number eight, AI is tackling the construction industry. Solvera, an AI-native engineering firm, secured a six-point-three-million-dollar pre-seed round led by Seedcamp. Solvera uses its proprietary AI to design and coordinate complex building engineering work, like HVAC and electrical systems. This early-stage funding will be used to expand its team and further develop its AI-powered operating system for automating building design.
• Rounding out our top ten are two seed-stage deals. At number nine, Zaria, a structured finance startup for digital assets, raised five-point-two million dollars led by Lightspeed. They're building infrastructure for collateral monitoring and are seeking a national trust bank charter. And at number ten, Shamrock AI raised five million dollars led by Endiya Partners. They're building an 'agentic assurance' platform to help enterprises reliably deploy and test AI agents for critical business operations.
• That's the top ten for today. Looking ahead, the key theme to watch is the rise of what Shamrock AI calls 'agentic assurance.' As companies deploy more autonomous AI agents, platforms like Shamrock's and Harmonic Security's, which manage, secure, and validate these agents, are becoming a critical new investment category. Expect to see more funding and M&A in this space. We'll be back tomorrow afternoon at three PM Pacific with the next deal flow.